Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Thanks again Rocky, rock-on. eom
Rocky, this evening on Kramers Mad money, they had Intel's COO on. He said their CEO just got back from South America on business and was talking about their new platform applications rolling out. Wasn't Tim Huff just in South America this past week per Mailman1's email correspondence with him? Sorry, can't find the message #. Might be a link there. TIA
CTKH, news
XRYM, chart
MIIS, chart
Rivet,CRZO?
SBAQ chart,
Rivet and all, good co. with rising revs. and in the oil @ gas biz. Only problem is it is canadian. Any thoughts or comments? Thinking about juumping onbooard.
SITI chart,
COCBF chart,
Rivet,break of $28.70?
Gold play.NG,
RHI chart.
Break above .22
Coming off double bottom.
SUNW.Coming up.
Rivet,great tutorial,thanks.Here is my scan on Stockcharts.com. Seems to work but am always a few days past the run. How can I get a more refined approach, or am I on the wrong track?TIA[type = stock] and [Close < 30] and [Volume > 100,000] and [aroon osc > 0] and [yesterday's aroon osc <= 0] and [AccDist Signal(14)> AccDist] and [country is US]
BGTH news.IOCircuit.
BioGentech Corp. (BGTH), a pharmaceutical company specializing in over-the-counter anti-allergy medications, announced the Division of Pulmonary and Allergy Drug Products at the US Food and Drug Administration (FDA) has completed its review of, and has approved the Company to proceed with, Phase III clinical trials for its new allergy drug Prehistin(TM). Based upon this review and approval, BioGentech has initiated Phase III clinical trials to study the ability of Prehistin to mitigate the symptoms of seasonal allergies (seasonal allergic rhinitis). Prehistin is a sub-lingual lozenge requiring no physician visits or injections. A successful outcome to these Phase III trials would open the door for Prehistin to become the first-ever over-the-counter drug whose action would reduce or potentially eliminate the symptoms of season allergies, as opposed to the current paradigm of attacking such symptoms through the use of antihistamines.
Additionally, BioGentech is preparing to implement additional studies based on this science. Currently, the Company is designing protocols to conduct clinical trials for supplementary indications for Prehistin. The indications sought will include perennial allergic rhinitis (year-round, indoor allergies), pediatric dosing, asthma and food allergies.
For further information please visit their website at http://www.biogentec.com.
Other active stocks are P-Com Inc. (PCOM), Shelron Group Inc. (SHRN), Sinovac Biotech Ltd. (SNVBF).
Double bottom.
Thanks Rivet, you are probably watching this one.
Rivet,my new scan gives me some charts like this,good?
Thank you,appreciate the response.
Rivet,one more try.BMMI, volume picking up.TIA
Thanks again,rivet
Rivet, been studying charts. Does UNFY look ready to turn?TIA
GEEX, double bottom watch.eom
thanks Rivet, been out for a while
Rivet, newbie here, awesome website! Am learning alot and really appreciate the links you have for research.I am looking at CLSI, could this be a symmetrical triangle or a descending? TIA